Tags agriculture agriculture Farming: seeds, crop protection, crop insurance, and moving and processing grain and other crops.
Theme · 6 companies · 0 report it as a revenue line
Sells it“We provide coverage to insurers that protect farmers and agricultural producers against the loss of crops via extreme weather (e.g., floods, hail, and drought) and the loss of revenue due to price fluctuation in the agricultural commodity market.”
Latest S-1 IPO prospectus Bankruptcy / going concern Accounting issue Impairment / charge · Filed Nov 16
Specialty insurer spanning agriculture and medical stop-loss; an entirely secondary offering pays existing holders.
Supplies it“Grain growth reflected strong Canadian and U.S. movements, including longer-haul Mexico traffic.”
Latest 10-Q Q3 FY2026 · Filed Oct 28
Longer grain hauls into Mexico and port-linked intermodal lifted revenue; higher fuel and compensation costs squeezed margins.
Revenue C$4.2B YoY +15.2% Net income C$917.0M YoY −0.3% Latest 8-K Dividend · Filed Oct 30
Quarterly dividend declared at $0.27 per common share, payable Jan. 25, 2027 to shareholders of record Dec. 31, 2026.
Latest 8-K Positive Earnings Guidance reaffirmed · Filed Oct 28
Grain and intermodal drove 15% Y/Y revenue growth, while higher fuel prices squeezed operating margins.
Latest 8-K Debt financing · Filed Sep 29
CPKC-guaranteed C$1.8B note offering will primarily refinance outstanding debt
Latest 8-K Leadership change · Filed Jul 29
Board succession plan elevates Gordon Trafton to Chair following Isabelle Courville’s retirement.
Sells it“Corteva’s seed and crop-protection products require costly testing and approvals that vary by country and may need periodic renewal.”
Latest 10-Q Q3 FY2026 Negative Restructuring Impairment / charge Legal / investigation · Filed Nov 12
Seed spin-off into Vylor removes an earnings cushion as Brazilian weakness and pricing pressure weigh on Crop Protection.
Revenue $2.5B YoY −6.1% Net income −$570.0M YoY −78.1% Latest 8-K Negative Guidance lowered Restructuring Impairment / charge · Filed Nov 12
Seed separation makes Vylor independent; FY2026 operating EBITDA guidance lowered to $1.10B–$1.125B
Latest 8-K Leadership change · Filed Oct 7
Separation brings Luke Kissam in as CEO and director as Charles Magro and other directors and officers resign.
Latest 8-K Governance change Debt financing · Filed Oct 7
Vylor completes $1.439B EIDP note exchange; indenture amendments modify noteholder rights across all three series.
Latest 8-K Positive Legal / investigation Deal pending · Filed Sep 30
District Court denies California’s bid to block Vylor seed spinoff; share distribution expected Oct. 1.
Latest S-1/A amended IPO prospectus Negative Bankruptcy / going concern Accounting issue Pre-revenue · Filed Oct 22
Develops single-seat electric aircraft for Crimson flying clubs; offering funds the transition from prototypes to a targeted 2028 commercial launch.
Supplies it“In addition, these products are used for chemical and materials applications including development of synthetic spider silk, nylon, rubber, fragrances, flavors and food additives; for food and agricultural applications including improving crop traits such as adding vitamins or improving drought tolerance, and engineering bacteria to deliver nitrogen at the root of plants.”
Latest 10-K FY2026 Positive · Filed Nov 16
AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.
Revenue $459.4M YoY +22.0% Net income −$130.2M YoY −67.6% Latest 10-Q Q3 FY2026 Legal / investigation · Filed Aug 3
Synthetic biology and therapeutics demand drove growth, but commercial and infrastructure spending widened operating losses.
Revenue $118.4M YoY +23.2% Net income −$35.1M vs $20.4M year ago Latest 8-K Positive Earnings New guidance Impairment / charge Legal / investigation · Filed Nov 12
AI drug discovery revenue assumption of $100M underpins FY2027 guidance for $550M–$560M in sales and positive adjusted EBITDA.
Latest 8-K Equity raise · Filed Aug 19
Resale registration covers shares issuable to Invenra under its stock purchase agreement with Twist Bioscience.
Latest 8-K Positive Contract / partnership · Filed Aug 18
Anthropic selected Twist to independently evaluate AI-designed proteins through scaled production and binding tests.
Latest 8-K Shareholder vote · Filed Feb 6
Stockholders elected directors, backed executive pay and ratified Ernst & Young as FY2026 auditor.
Sells it“Bulk revenue rose 10% on flat volume: stronger export grain, renewable fuels, ethanol and feedstocks offset weaker coal, wheat, soybean meal and fertilizer.”
Latest 10-Q Q3 FY2026 Positive Legal / investigation · Filed Oct 22
Intermodal demand and fuel surcharges drove growth, while service weakened and the Norfolk Southern deal kept buybacks paused.
Revenue $7.2B YoY +15.3% Net income $2.1B YoY +16.1% Latest 8-K Positive Earnings Guidance reaffirmed · Filed Oct 22
Carload growth and pricing powered gains, but higher fuel prices added 140 bp to Union Pacific’s operating ratio.
Latest 8-K CEO/CFO change · Filed Oct 16
CFO Jennifer Hamann plans to retire in early 2027 after 35 years at Union Pacific.
No companies have a recent 8-K matching these events. Show all 8-K events
No companies in the selected roles.